Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Avadel Pharmaceuticals PLC. (AVDL) had Return on Tangible Equity of -85.65% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$169.12M |
|
$-48.83M |
|
$15.28M |
|
$153.84M |
|
$211.52M |
|
$-42.40M |
|
$-6.68M |
|
$-49.08M |
|
$-49.08M |
|
$-48.83M |
|
$-48.83M |
|
$-48.83M |
|
$-48.83M |
|
$-42.40M |
|
$-39.72M |
|
95.14M |
|
95.14M |
|
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$134.21M |
|
$0.45M |
|
$30.03M |
|
$164.24M |
|
$48.83M |
|
-- |
|
$41.55M |
|
$90.39M |
|
$73.85M |
|
$57.01M |
|
$73.85M |
|
96.52M |
|
| Cash Flow Statement Financials | |
$-46.91M |
|
$51.78M |
|
$15.97M |
|
$31.17M |
|
$51.37M |
|
$20.20M |
|
$20.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
90.97% |
|
-25.07% |
|
-25.07% |
|
-23.49% |
|
-29.02% |
|
-28.87% |
|
$-46.91M |
|
-- |
|
-- |
|
-- |
|
1.03 |
|
0.75 |
|
4.96 |
|
73.59 |
|
-66.12% |
|
|
Return on Tangible Equity |
-85.65% |
-29.73% |
|
-66.12% |
|
$0.77 |
|
$-0.49 |
|
$-0.49 |
|